Norway vs Western Pacific (WHO region): Previously treated cases tested for RR-/MDR-TB
Norway
100.0%
in 2024
Western Pacific (WHO region)
86.0%
in 2024
Norway rank
1st
Western Pacific (WHO region) rank
3rd
Previously treated cases tested for RR-/MDR-TB over time
- Norway
- Western Pacific (WHO region)
How they compare
Norway currently reports 100.0% against 86.0% in Western Pacific (WHO region), a difference of 14.0%.
That makes Norway's figure about 1.2 times Western Pacific (WHO region)'s.
The two have swapped places 6 times across 20 shared years of data; in 2005 it was Norway ahead.
Norway ranks 1st and Western Pacific (WHO region) ranks 3rd of 180 countries.
Norway has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Norway | Western Pacific (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 60.0% | 1.0% | 59.0% | Norway |
| 2010s | 62.5% | 54.9% | 7.6% | Norway |
| 2020s | 89.4% | 89.2% | 0.2% | Norway |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Norway or Western Pacific (WHO region)?
- Norway, at 100.0% against 86.0% in Western Pacific (WHO region) as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Norway and Western Pacific (WHO region)?
- 14.0%, with Norway ahead.
- How many years of comparable data are there for Norway and Western Pacific (WHO region)?
- 20 years are reported by both, from 2005 to 2024.
- How do Norway and Western Pacific (WHO region) rank globally for previously treated cases tested for rr-/mdr-tb?
- Norway ranks 1st and Western Pacific (WHO region) ranks 3rd of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.